We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Sheraz
Markar
s.markar@imperial.ac.uk
Dr
Sheraz
Markar
s.markar@imperial.ac.uk
Karina
Tukanova
karina.tukanova17@imperial.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The incidence of oesophageal malignancy is increasing annually; representing 7% of all gastrointestinal malignancies internationally.1,2,3 Despite improvements in staging modalities, surgical techniques and perioperative care, cure rates following surgical resection alone for locoregional cancer remain low, with an overall 5-year survival ranging from 10–30% internationally.4,5,6 In England and Wales, approximately 13 000 patients are diagnosed with oesophago-gastric cancer each year, being the fifth most common malignancy, with an overall survival ranging between 17% and 19% at five years.7
Surgery remains the mainstay of curative treatment for oesophageal cancer. Most commonly in the UK, surgery is performed by a two- or three-stage procedure, including both open and minimally invasive surgical access.8
Rationale
Open oesophagectomy for cancer commonly involves thoracotomy with a high rate of postoperative pulmonary complications (30–50%).9,10 Antonowicz S. et al recently presented a population-based cohort study of 90,000 oesophageal and colorectal cancer surgery patients on the International Society for Diseases of the Esophagus (ISDE) and identified that oesophagectomy compared with colorectal cancer surgery was associated with an increased rate of respiratory cause of death after 90-days, after adjustment for baseline medical comorbidities (HR=2.52; 95%CI 2.14–2.96) and postoperative complications (HR=2.25; 95%CI 1.93–2.63). Totally minimally invasive oesophagectomy has been shown to reduce pulmonary infections by 20%.11,12 Similarly, enhanced recovery programmes with early mobilisation protocols and chest physiotherapy have been shown to reduce pulmonary complication rates.13,14 However, no data is currently available regarding the long-term respiratory function, quality of life and chest wall function in oesophageal cancer survivors. Another trial we presented as an abstract on ISDE is the LASER study from 15 European centres including over 800 survivors and we showed that 24% of the patients have thoracotomy related pain and 42% have persistent respiratory symptoms.
4. STUDY AIMS
4.1 Objectives
The objectives of this study are to:
1. Objectively measure chest wall movement using 3D motion capture system.
2. Develop a wearable measurement system that has the potential to remotely monitor chest wall movement.
3. To pilot test the reliability, validity and acceptability of this system to oesophagectomy patients.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
5.2 Exclusion Criteria Any participant who: • Lacks capacity or is unable to provide informed consent. • Any patient below 18 years of age or over 90 years of age. • Any patient with evidence of cancer recurrence or on-going postoperative complication at more than one year following surgery for oesophageal cancer. • Any pregnant participant.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Karina
Tukanova
karina.tukanova17@imperial.ac.uk
Dr
Sheraz
Markar
s.markar@imperial.ac.uk
Dr
Sheraz
Markar
s.markar@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by NIHR Imperial Biomedical Research Centre .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41815
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
